These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9212139)

  • 1. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
    Ording H; Glahn K; Gardi T; Fagerlund T; Bendixen D
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility.
    Weigl LG; Ludwig-Papst C; Kress HG
    Anesth Analg; 2004 Jul; 99(1):103-107. PubMed ID: 15281512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
    Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
    Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility.
    Baur CP; Bellon L; Felleiter P; Fiege M; Fricker R; Glahn K; Heffron JJ; Herrmann-Frank A; Jurkat-Rott K; Klingler W; Lehane M; Ording H; Tegazzin V; Wappler F; Georgieff M; Lehmann-Horn F
    Anesth Analg; 2000 Jan; 90(1):200-5. PubMed ID: 10625004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Fiege M; Wappler F; Scholz J; Weisshorn R; von Richthofen V; Schulte am Esch J
    J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies.
    Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P
    Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
    Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Adamantidis MM; Reyford GH; Imbenotte M; Cordonnier C
    Br J Anaesth; 1990 Dec; 65(6):791-5. PubMed ID: 1702303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia].
    Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Rumberger E; Löscher W; Schulte am Esch J
    Anaesthesist; 1995 Aug; 44(8):538-44. PubMed ID: 7573901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
    Bina S; Cowan G; Karaian J; Muldoon S; Mongan P; Bünger R
    Anesthesiology; 2006 Jan; 104(1):90-100. PubMed ID: 16394695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Wappler F; Scholz J; Fiege M; Richter A; Steinfath M; Weisshorn R; Schulte am Esch J
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Oct; 360(4):376-81. PubMed ID: 10551274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is a presymptomatic malignant hyperthermia in-vitro diagnosis with 4-chloro-3-ethyl phenol possible? A study using porcine skeletal preparations].
    Gerbershagen MU; Wappler F; Fiege M; Weisshorn R; Kolodzie K; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Feb; 39(2):81-6. PubMed ID: 14767797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
    Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
    Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.